Jin Kwan Kim

USPTO Granted Patents = 17 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 8.2

ph-index = 2

Forward Citations = 32(Granted Patents)

Location History:

Seoul, KR (2002 - 2017)
Suwon-si, KR (2010 - 2021)
Gyeonggi-do, KR (2018 - 2021)

Company Filing History:

7 out of 540

Amorepacific Corporation

patents

5 out of 6

Dong-a Socio Holdings Co., Ltd.

Years Active: 2002-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378224 - Heteroaryl compounds and their use as Mer inhibitors (2025-08-05),

2. 12195446 - Heteroaryl compounds and their use as therapeutic drugs (2025-01-14),

3. 11197903 - Composition containing a bean extract for improving blood circulation and vascular health and method for improving blood circulation and vascular health (2021-12-14),

4. 10947215 - Heteroaryl compounds and their use as therapeutic drugs (2021-03-16),

5. 10913730 - Heteroaryl compounds and their use as Mer inhibitors (2021-02-09),

6. 10125118 - Heteroaryl compounds and their use as therapeutic drugs (2018-11-13),

7. 9646956 - Light emitting device package (2017-05-09),

8. 9064773 - Light emitting device package (2015-06-23),

9. 8968802 - Composition containing colored-bean extract (2015-03-03),

10. 8691855 - Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same (2014-04-08),

11. 8557872 - Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same (2013-10-15),

12. 8071650 - Thiourea derivatives and the pharmaceutical compositions containing the same (2011-12-06),

13. 7960584 - Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same (2011-06-14),

14. 7858621 - Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same (2010-12-28),

15. 7763657 - Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same (2010-07-27),

Title: The Innovative Contributions of Jin Kwan Kim

Introduction: Jin Kwan Kim is a notable inventor based in Suwon-si, South Korea, who has made significant contributions in the field of therapeutic drugs. With 16 patents to his name, his work focuses primarily on developing compounds with potential medical applications.

Latest Patents: Among his latest patents, Jin Kwan Kim has developed heteroaryl compounds that serve as therapeutic drugs. This particular invention offers compounds capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). It includes pharmaceutical compositions, methods for preparing these compounds, and their use as potential medicaments. The MERTK inhibitory compounds he has created display marked potency, indicating a promising future for pharmaceutical interventions in cancer treatment and other diseases linked to MERTK dysregulation.

Another significant patent includes a composition containing a bean extract aimed at improving blood circulation and vascular health. Extracted with low-concentration, low-grade alcohol, this composition demonstrates excellent effects in enhancing blood circulation, combating obesity, and preventing conditions like diabetes and hyperlipidemia. The related methods further outline approaches to improve vascular health and manage symptoms associated with these ailments.

Career Highlights: Jin Kwan Kim has further honed his expertise by working with prominent companies including Amorepacific Corporation and Dong-a Socio Holdings Co., Ltd. His experience in these firms has bolstered his research and development capabilities, driving his innovation in therapeutic compounds.

Collaborations: Throughout his career, Jin has collaborated with esteemed professionals such as Kyung Min Lim and Yeon Su Jeong. These collaborations have enriched his work, contributing to the successful development of his patented inventions.

Conclusion: Jin Kwan Kim stands out as a prolific inventor whose contributions have the potential to advance medical science and improve patient care. With a solid portfolio of patents reflecting both innovation and practical application, he continues to be a pertinent figure in the realm of therapeutic drug development.

This text is generated by artificial intelligence and may not be accurate.